EMA Consultation on Reflection Paper on Methodological Aspects in Confirmatory Platform Trials
On 19 October 2026, the European Medicines Agency (EMA) launched a public consultation on its draft Reflection Paper on Methodological Aspects in Confirmatory Platform Trials. The document examines methodological considerations for designing platform trials that can generate reliable and interpretable evidence to support regulatory decision-making, including marketing authorisation applications.
Overview
Authority | EMA; Committee for Medicinal Products for Human Use (CHMP) / Methodology Working Party |
Date | 19 October 2026 |
Focus | Methodological considerations for confirmatory platform trials |
Type | Public consultation on a draft reflection paper |
Deadline for comments | 31 January 2027 |
What is this about?
Platform trials investigate multiple treatments within a single randomised clinical trial framework, with treatment arms potentially being added or discontinued over time. These designs can improve clinical development efficiency but also introduce methodological challenges concerning statistical validity, comparability and interpretation of results.
As platform trials become increasingly relevant to marketing authorisation applications, the EMA aims to clarify the conditions under which they can provide sufficiently robust evidence for confirmatory purposes.
The reflection paper complements existing methodological guidance on topics such as multiplicity and adaptive designs. It focuses on studies intended to provide pivotal evidence for regulatory decision-making. Operational aspects of trial conduct and clinical trial application procedures are outside its scope.
Consultation details
The draft reflection paper addresses several methodological considerations relevant to confirmatory platform trials:
Pre-specification: Trial objectives, estimands, adaptation strategies and statistical testing approaches should be defined prospectively to preserve the confirmatory nature of the evidence.
Randomisation: Fixed allocation ratios are recommended for individual comparisons. The EMA does not support response-adaptive randomisation because of methodological concerns.
Control groups: Concurrent controls are strongly preferred. Non-concurrent controls are generally not considered acceptable for the primary analysis of the primary endpoint, and any proposed use would require a particularly strong methodological justification.
Multiplicity: Strong control of the family-wise error rate is expected for relevant hypothesis families, while adjustment across all platform hypotheses may not always be necessary.
Trial integrity: Appropriate blinding and restrictions on access to emerging results are important to minimise bias, particularly when treatment arms continue after interim analyses.
Design justification: Sample size, statistical power, estimands and other operating characteristics should be carefully evaluated, including through simulations where appropriate.
Submitting comments
Stakeholders wishing to participate in the consultation can submit their comments through the dedicated EUSurvey form until 31 January 2027.
The consultation materials include an Excel template for preparing comments. Participants should complete the workbook and upload it through the dedicated EUSurvey submission form.
Useful links
Access the consultation materials and submission tools.
Consultation overview and supporting information
Full draft reflection paper for review
Stakeholder comment template (Excel) ➜ Download the Excel workbook for preparing comments
Submit a comment — EUSurvey ➜ Official online form for submitting the completed comment template
Key timeline
Start of public consultation: 19 October 2026
Deadline for comments: 31 January 2027
Why this matters
The draft reflection paper provides an important indication of the EMA's methodological expectations for confirmatory platform trials. Its recommendations may influence future clinical development strategies, particularly where sponsors intend to use platform trials as pivotal evidence in marketing authorisation applications.
The proposed approaches to concurrent controls, randomisation, multiplicity and trial integrity may have significant implications for study design, statistical planning and evidence-generation strategies.
The consultation provides an opportunity for stakeholders to highlight practical challenges, propose methodological alternatives and identify areas where additional regulatory clarification may be beneficial before the document is finalised.
Who should consider responding?
This consultation may be particularly relevant for:
Pharmaceutical and biotechnology companies planning confirmatory platform trials
Academic sponsors and research networks conducting platform trial programmes
Biostatisticians and clinical development professionals involved in complex trial designs
Regulatory affairs teams responsible for clinical development and marketing authorisation strategies
Contract research organisations supporting platform trials and adaptive study designs
Practical implications
Stakeholders may wish to consider:
Reviewing planned or ongoing platform trials against the methodological positions outlined in the draft
Assessing whether randomisation strategies and the selection of control groups are consistent with the proposed recommendations
Evaluating the implications of multiplicity control, pre-specification and trial integrity requirements for study design
Identifying methodological or operational challenges that may warrant further clarification
How we can help
We support organisations in:
Assessing the relevance and implications of regulatory consultations
Evaluating operational, compliance and implementation considerations
Identifying strategic risks, opportunities and areas for engagement
Developing evidence-based and impactful responses to regulatory authorities
Contact us if you would like to discuss how this consultation may affect your organisation, submission strategy or planned regulatory activities.
Stay informed
We highlight selected regulatory consultations and policy developments that may be relevant to affected stakeholders. Our updates focus on opportunities to understand emerging approaches and, where appropriate, contribute comments before they are adopted.